“The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India,” said Murali Ramachandra, CEO of Aurigene Oncology. “We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma.”
